Effects of non-statin antilipemic drugs on vascular endothelial function in patients with type 2 diabetes with hypercholesterolemia
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Type 2 diabetes is a risk factor for atherosclerosis because concomitant hypercholesterolemia further exacerbates hyperglycemia. We compared the efficacy of non-statin and non-fibrate antilipemic drugs in type 2 diabetes patients with hypercholesterolemia, and evaluated the flow-mediated vasodilation (FMD), a marker of early atherosclerotic changes.
Patients and methods
Fifty outpatients (aged 39–79) with type 2 diabetes and low-density lipoprotein cholesterol levels of ≥120 mg/dl were randomly allocated into two groups: 23 patients first received ezetimibe for 4 months followed by eicosapentaenoic acid (EPA) for the next 4 months, and 27 patients first received eicosapentaenoic acid for 4 months followed by ezetimibe for the next 4 months. Glycated hemoglobin and serum lipid levels were measured before and 4 and 8 months after treatment. Ankle brachial pressure index, intimal medial thickness, and FMD were measured in 35 patients. A pretreatment group (group 0) was added. We compared data from groups 0, A (subjects receiving ezetimibe), and B (subjects receiving EPA) during and after treatment.
Non-high-density lipoprotein cholesterol levels decreased significantly in group A compared with groups 0 and B. No significant difference in serum high-density lipoprotein cholesterol levels was observed among the groups, whereas triglyceride levels decreased significantly in group B compared with group 0. FMD increased significantly in groups A and B compared with group 0.
FMD investigation may affect the evaluation of early atherosclerotic changes, and the administration of ezetimibe and EPA may be useful for patients with type 2 diabetes with hypercholesterolemia because it improves vascular endothelial function.
- Lerman A, Zeiher AM. Endothelial function—cardiac events. Circulation. 2005;111:363–8. CrossRef
- Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285–95.
- Cohn JN, Quyyumi AA, Hollenberg NK et al. Surrogate markers for cardiovascular disease: functional markers. Circulation. 2004; 109(suppl IV):31–46.
- Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585–90. CrossRef
- Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33(3):171–87. CrossRef
- Harris WS. N-3 Fatty acids and serum lipoprotein: human studies. Am J Clin Nutr. 1997;65(suppl):1645S–54S.
- Tagawa H, Shimokawa H, Tagawa T, et al. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol. 1999;33:633–40. CrossRef
- Yano T, Kawano H, Yamashita M, et al. Effects of ethyl-all-cis-5,8,11,14,17-icosapentaenoate (EPA-E), pravastatin and their combination serum lipids and intimal thickening of cuff-sheathed carotid artery in rabbits. Life Sci. 1997;61:2007–15.
- Sato M, Katsuki Y, Kanehiro H, et al. Effects of ethyl all-cis-5,8,11,14,17-icosapentaenoate on the physical properties of arterial walls in high cholesterol diet-fed rabbits. J Cardiovasc Pharmacol. 1993;22:1–9. CrossRef
- Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids. 2001;35:1007–24. CrossRef
- Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr. 1997;65(suppl):1687S–98S.
- West SG, Hecker KD, Mustad VA, et al. Acute effects of monounsaturated fatty acids with and without omega-3 fatty acids on vascular reactivity in individuals with type 2 diabetes. Diabetologia. 2005;48(1):113–22. CrossRef
- Goodfellow J, Bellamy MF, Ramsey MW, et al. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol. 2000;35(2):265–70. CrossRef
- Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–43. CrossRef
- Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima–media thickness. N Engl J Med. 2009;361(22):2113–22. CrossRef
- Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima–media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol. 2009;49(7):838–47.
- Miyashita Y, Endo K, Saiki A, et al. Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb. 2010;17(10):1070–6. CrossRef
- Maki-Petaja KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll. 2007;50(9):852–8. CrossRef
- Yunoki K, Nakamura K, Miyoshi T, et al. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis. 2011;217(2):486–91. CrossRef
- Nakamura T, Hirano M, Kitta Y, et al. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol. 2012;60(1):12–7. CrossRef
- Yunoki K, Nakamura K, Miyoshi T, et al. Impact of hypertriglyceridemia on endothelial dysfunction during statin ± ezetimibe therapy in patients with coronary heart disease. Am J Cardiol. 2011;108(3):333–9. CrossRef
- Ishiguro J, Tada T, Ogihara T, et al. Studies on the metabolic disposition of ethyl eicosapentaenoate (EPA-E) in rats and dogs. Drug Metab Pharmacokinet. 1987;2(6):683–702.
- Patrick JE, Kosoglou T, Stauber KL, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos. 2002;30(4):430–7. CrossRef
- Sever PS, Poulter NR, Dahlof B, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J. 2008;29(4):499–508.
- Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74. CrossRef
- Effects of non-statin antilipemic drugs on vascular endothelial function in patients with type 2 diabetes with hypercholesterolemia
Volume 5, Issue 3 , pp 175-180
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Flow-mediated vasodilation
- Eicosapentaenoic acid
- Industry Sectors
- Author Affiliations
- 1. Department of Diabetology and Endocrinology, Osaka Saiseikai Noe Hospital, Osaka, Japan
- 2. Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- 3. Department of Clinical Examination, Osaka Saiseikai Noe Hospital, Osaka, Japan
- 4. Department of Nutrition Science, Faculty of Health and Welfare Science, Okayama Prefectural University, Okayama, Japan